March 23, 2020 / 12:49 PM / 13 days ago

BRIEF-Stoke Therapeutics - Expects Enrollment Of Patients In Part A Of Phase 1/2A Monarch Single-Ascending Dose Study Of STK-001 In Second Half Of 2020

March 23 (Reuters) - Stoke Therapeutics Inc:

* STOKE THERAPEUTICS - EXPECTS BENROLLMENT OF PATIENTS IN PART A OF PHASE 1/2A MONARCH SINGLE-ASCENDING DOSE STUDY OF STK-001 IN SECOND HALF OF 2020

* STOKE THERAPEUTICS - NOMINATION OF A SECOND PRODUCT CANDIDATE FOR TREATMENT OF AN ADDITIONAL GENETIC DISEASE EXPECTED IN SECOND HALF OF 2020

* STOKE THERAPEUTICS - ADDITIONAL TOXICOLOGY STUDIES NOW UNDERWAY; PRELIMINARY DATA FROM MONARCH STUDY STILL ANTICIPATED IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below